Rocket Pharmaceuticals to build AAV manufacturing facility in NJ

By The Science Advisory Board staff writers

January 12, 2021 -- Rocket Pharmaceuticals has announced the buildout for a new site in Cranbury, NJ, that will support Rocket's pipeline for lentivirus and adeno-associated virus (AAV) gene therapies.

The 103,720-sq-ft facility will also serve as a new headquarters for Rocket as well as a location for research and development (R&D) and chemistry, manufacturing and controls (CMC) operation. It also has space for potential future expansion and commercialization.

Rocket Pharmaceuticals headquarters.
Rocket Pharmaceuticals headquarters. Image courtesy of Rocket Pharmaceuticals.

Roughly half of the space is earmarked for AAV current good manufacturing practice (cGMP) production, while the other half features state-of-the-art R&D labs to support CMC development. Dr. Gaurav Shah, the president and CEO of Rocket, said the facility is crucial to fulfilling the company's mission to bring five curative therapies to rare disease patients in the next four years.

Rocket intends to begin the first cGMP production at the facility in 2021. The company also said it plans to use the facility for a planned study evaluating the company's first AAV-based gene therapy for the treatment of Danon Disease.

Adverum to build new AAV manufacturing facility in NC
Adverum Biotechnologies plans to build a new good manufacturing practice gene therapy manufacturing facility in North Carolina to internalize its adeno-associated...
BrickBio spins out EnCapsid with new AAV platform
BrickBio has spun out a new Boston-based gene therapy company, EnCapsid, focused on developing enhanced adeno-associated virus (AAV) delivery vectors...
Selecta Biosciences validates tech that could improve gene therapies
Selecta Biosciences has achieved preclinical data validating its ImmTOR platform to enhance the efficacy, safety, and durability of adeno-associated viral...
ViGeneron, Biogen to develop AAV-based gene therapies for eye disease
ViGeneron and Biogen have signed a global collaboration and licensing agreement to develop and commercialize gene therapy products based on adeno-associated...
Shape Therapeutics unveils advanced AAV capsid discovery platform
Shape Therapeutics has unveiled its adeno-associated virus (AAV) discovery platform, AAVid capsid, and results from its first AAV5 variant library in...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter